Company profile
ROCKET PHARMACEUTICALS, INC.
NASDAQ:RCKTBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Marnetegragene Autotemcel | approved | — | 2 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03812263 | phase1_2 | completed | 2019-08-30 | 2023-09-12 | Rocket Pharmaceuticals Inc. | A Clinical Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I |
| NCT03814408 | phase1 | unknown | 2019-01-11 | 2020-12-01 | Rocket Pharmaceuticals Inc. | A Clinical Trial to Evaluate the Safety of RP-L102 in Pediatric Subjects With Fanconi Anemia Subtype A |
| NCT06092034 | phase2 | recruiting | 2023-09-05 | 2028-04-01 | Rocket Pharmaceuticals Inc. | A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease |
| NCT03825783 | phase1 | withdrawn | 2019-04-15 | 2021-10-01 | Rocket Pharmaceuticals Inc. | A Gene Therapy Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I |
| NCT07137338 | phase1 | recruiting | 2026-06-01 | 2029-06-01 | Rocket Pharmaceuticals Inc. | A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| BLA 125806 | BLA | Rocket Pharmaceuticals Inc | ||||
Loading… | ||||||